Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesenchymal stem cell therapy (Hexun Biosciences)
- Development stage
- Phase 2
- Lead developer
- Hexun Biosciences
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
Hexun Biosciences is developing an allogeneic mesenchymal stem cell (MSC) therapy for the treatment of heart failure associated with coronary artery disease (HF-CAD). The therapy leverages the regenerative and immunomodulatory properties of MSCs, which are capable of multilineage differentiation and secreting paracrine factors to promote tissue repair and reduce inflammation in the damaged myocardium. The program is currently in Phase 1 clinical development, specifically targeting safety in severe heart failure patients before potentially expanding to the broader CAD population. Hexun is also exploring the same MSC platform for other indications including frailty, chronic kidney disease, and graft-versus-host disease.
- Other names
- HF-CAD MSC Cell TherapyCAD MSC Cell TherapyFrailty MSC Cell TherapyCKD MSC Cell TherapyGVHD MSC Cell TherapyMSC cell therapy
Beyond the preview
Go deeper on mesenchymal stem cell therapy (Hexun Biosciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesenchymal stem cell therapy (Hexun Biosciences).